Binimetinib vs Cobimetinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Melanoma
Shared mechanism: MEK1/2 · full Melanoma pipeline
Binimetinib
Marketed by Pfizer and partners
NCT01763164 · Phase 3 · completed
The randomized, active-controlled trial compared binimetinib with dacarbazine in 402 participants, using progression-free survival assessed by RECIST as its primary clinical endpoint. Progression-free survival favored binimetinib (p<0.001), but the open-label design limits the strength of the evidence.
Next expected readout: January 2027 · NCT03947385 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization to the date of the first documented PD or death, whichever occurred first (maximum up to 77 weeks for binimetinib arm; maximum up to 61 weeks for dacarbazine arm)): Binimetinib (MEK162) 2.83 Months (95% CI 2.76 to 3.55) | Dacarbazine 1.51 Months (95% CI 1.48 to 1.71) (met)
Result source: NCT01763164
Cobimetinib
Marketed by Roche and partners
NCT01689519 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled trial with 495 participants. Its primary clinical endpoint, progression-free survival, was significantly better with cobimetinib plus vemurafenib than with vemurafenib plus placebo (hazard ratio 0.51, p=0.0001).
Next expected readout: December 2026 · NCT04835805 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cobimetinib: registry results are on file for Melanoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Binimetinib's landscape · Cobimetinib's landscape